X

Clinical Trials

Contact Us

GU Cancer

EA8185

Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)


A031803

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer


A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events


A031704

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]


S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer


2018-01 (MBMC only) (temporarily closed)

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors


NCI 10231 (MBMC only)

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study


A031702 (Penile Cohort Suspended 3/13/20/ Miscellaneous GU Tract Variants Cohort suspended 7/20/20/ Small Cell Carcinoma of the Bladder Cohort Suspended 10/14/20/ Adenocarcinoma of the Bladder Cohort Closed 11/9/20))

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors


S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer


A031701

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations